Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children.
- Author:
Sun Min LIM
1
;
Cheol Joo YOO
;
Jung Woo HAN
;
Yong Jin CHO
;
Soo Hee KIM
;
Joong Bae AHN
;
Sun Young RHA
;
Sang Joon SHIN
;
Hyun Cheol CHUNG
;
Woo Ick YANG
;
Kyoo Ho SHIN
;
Jae Kyung RHO
;
Hyo Song KIM
Author Information
- Publication Type:Original Article
- Keywords: Rhabdomyosarcoma; Ewing sarcoma; Primitive neuroectodermal tumors; Desmoplastic small round-cell tumor
- MeSH: Adult*; Child*; Classification; Demography; Desmoplastic Small Round Cell Tumor; Disease-Free Survival; Follow-Up Studies; Humans; Incidence*; Multivariate Analysis; Neoplasm Metastasis; Neuroectodermal Tumors, Primitive; Prognosis; Proportional Hazards Models; Retrospective Studies; Rhabdomyosarcoma; Sarcoma*; Sarcoma, Ewing
- From:Cancer Research and Treatment 2015;47(1):9-17
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Pediatric-type sarcomas such as rhabdomyosarcoma (RMS), Ewing sarcoma (EWS), primitive neuroectodermal tumor (PNET), and desmoplastic small round-cell tumor (DSRCT) are rare in adults, with limited studies on their prognosis and optimal treatment strategies. We aimed to examine the outcome of children and adult patients with RMS, EWS, PNET, and DSRCT and relevant prognostic factors. MATERIALS AND METHODS: We retrospectively reviewed 220 pediatric-type sarcoma patients at a single institution between 1985 and 2011. Comparisons were made in order to examine differences in demographics, disease characteristics, and survival. Survival analyses were performed using the Kaplan-Meier method with log-rank tests and Cox proportional hazards models. RESULTS: A total of 220 consecutive patients were identified at our institute. Median age was 15.6 years (range, 0 to 81 years) and there were 108 children (49%) and 112 adult patients (51%). According to histological classification, 106 patients (48.2%) had RMS, 60 (27.3%) had EWS, 50 (22.7%) had PNET, and 4 (1.8%) had DSRCT. With a median follow-up period of 6.6 years, the estimated median overall survival (OS) of all patients was 75 months (95% confidence interval [CI], 27.2 to 122.8 months) and median event-free survival (EFS) for all patients was 11 months (95% CI, 8.8 to 13.2 months). No significant difference in OS and EFS was observed between adults and children. In multivariate analysis, distant metastasis (hazard ratio [HR], 1.617; 95% CI, 1.022 to 2.557; p=0.040) and no debulking surgery (HR, 1.443; 95% CI, 1.104 to 1.812; p=0.012) showed independent association with worse OS. CONCLUSION: Metastatic disease and no surgical treatment are poor prognostic factors for OS among pediatric-type sarcomas for both adults and children.
